Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: EIF5B

Gene summary for EIF5B

Gene summary.

Gene information	Species	Human
	Gene symbol	EIF5B
	Gene ID	9669
	Gene name	eukaryotic translation initiation factor 5B
	Gene Alias	IF2
	Cytomap	2q11.2
	Gene Type	protein-coding
	GO ID	GO:0006412
	UniProtAcc	O60841

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
9669	EIF5B	HTA11_3410_2000001011	Human	Colorectum	AD	1.05e-07	-4.56e-01	0.0155
9669	EIF5B	HTA11_866_2000001011	Human	Colorectum	AD	1.90e-02	-2.02e-01	-0.1001
9669	EIF5B	A015-C-203	Human	Colorectum	FAP	4.53e-20	3.33e-02	-0.1294
9669	EIF5B	A015-C-204	Human	Colorectum	FAP	6.51e-04	2.60e-01	-0.0228
9669	EIF5B	A014-C-040	Human	Colorectum	FAP	1.02e-02	3.05e-01	-0.1184
9669	EIF5B	A002-C-201	Human	Colorectum	FAP	9.30e-06	-4.48e-02	0.0324
9669	EIF5B	A001-C-119	Human	Colorectum	FAP	1.33e-03	2.11e-01	-0.1557
9669	EIF5B	A001-C-108	Human	Colorectum	FAP	1.67e-18	3.58e-01	-0.0272
9669	EIF5B	A002-C-205	Human	Colorectum	FAP	1.14e-20	3.13e-01	-0.1236
9669	EIF5B	A001-C-104	Human	Colorectum	FAP	4.46e-05	3.12e-01	0.0184
9669	EIF5B	A015-C-006	Human	Colorectum	FAP	5.25e-22	5.21e-01	-0.0994
9669	EIF5B	A015-C-106	Human	Colorectum	FAP	1.89e-10	2.32e-01	-0.0511
9669	EIF5B	A002-C-114	Human	Colorectum	FAP	1.34e-15	2.09e-01	-0.1561
9669	EIF5B	A015-C-104	Human	Colorectum	FAP	1.08e-27	1.85e-01	-0.1899
9669	EIF5B	A001-C-014	Human	Colorectum	FAP	4.57e-14	2.71e-01	0.0135
9669	EIF5B	A002-C-016	Human	Colorectum	FAP	8.75e-19	1.81e-01	0.0521
9669	EIF5B	A015-C-002	Human	Colorectum	FAP	3.70e-13	4.05e-01	-0.0763
9669	EIF5B	A001-C-007	Human	Colorectum	CRC	5.72e-06	5.29e-01	0.1899
9669	EIF5B	A001-C-203	Human	Colorectum	FAP	1.21e-10	1.90e-01	-0.0481
9669	EIF5B	A002-C-116	Human	Colorectum	FAP	5.88e-24	-4.53e-02	-0.0452

Page: 1 2 3 4 5 6 7 8 9 10

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:0006417	Colorectum	AD	regulation of translation	141/3918	468/18723	1.32e-06	4.22e-05	141
GO:0006413	Colorectum	AD	translational initiation	45/3918	118/18723	1.35e-05	2.92e-04	45
GO:0006446	Colorectum	AD	regulation of translational initiation	28/3918	79/18723	2.02e-03	1.63e-02	28
GO:00064174	Colorectum	FAP	regulation of translation	111/2622	468/18723	8.47e-09	1.13e-06	111
GO:00064463	Colorectum	FAP	regulation of translational initiation	26/2622	79/18723	1.54e-05	4.01e-04	26
GO:00064134	Colorectum	FAP	translational initiation	34/2622	118/18723	2.13e-05	5.12e-04	34
GO:00064175	Colorectum	CRC	regulation of translation	82/2078	468/18723	1.79e-05	5.40e-04	82
GO:000641310	Endometrium	AEH	translational initiation	42/2100	118/18723	2.68e-12	4.67e-10	42
GO:000641716	Endometrium	AEH	regulation of translation	94/2100	468/18723	1.14e-08	7.62e-07	94
GO:00064467	Endometrium	AEH	regulation of translational initiation	25/2100	79/18723	8.99e-07	3.19e-05	25
GO:000641315	Endometrium	EEC	translational initiation	42/2168	118/18723	7.65e-12	1.24e-09	42
GO:000641717	Endometrium	EEC	regulation of translation	94/2168	468/18723	5.37e-08	2.88e-06	94
GO:000644614	Endometrium	EEC	regulation of translational initiation	25/2168	79/18723	1.62e-06	5.03e-05	25
GO:000641727	Esophagus	HGIN	regulation of translation	139/2587	468/18723	1.46e-19	7.98e-17	139
GO:000641320	Esophagus	HGIN	translational initiation	55/2587	118/18723	7.33e-18	2.31e-15	55
GO:000644610	Esophagus	HGIN	regulation of translational initiation	34/2587	79/18723	2.09e-10	1.97e-08	34
GO:0006413110	Esophagus	ESCC	translational initiation	100/8552	118/18723	1.16e-18	1.25e-16	100
GO:0006417111	Esophagus	ESCC	regulation of translation	304/8552	468/18723	1.53e-17	1.33e-15	304
GO:000644617	Esophagus	ESCC	regulation of translational initiation	65/8552	79/18723	2.04e-11	7.07e-10	65
GO:000641312	Liver	Cirrhotic	translational initiation	76/4634	118/18723	8.36e-20	2.18e-17	76

Page: 1 2 3

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

EIF5B

SNV

Missense_Mutation

c.2817N>T

p.Glu939Asp

p.E939D

O60841

protein_coding

tolerated(0.13)

possibly_damaging(0.605)

TCGA-A2-A25A-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unspecific

Cytoxan

EIF5B

SNV

Missense_Mutation

c.2161G>C

p.Asp721His

p.D721H

O60841

protein_coding

deleterious(0)

probably_damaging(0.998)

TCGA-A8-A085-01

Breast

breast invasive carcinoma

Male

<65

I/II

Hormone Therapy

tamoxiphen

EIF5B

SNV

Missense_Mutation

c.2641N>T

p.Arg881Cys

p.R881C

O60841

protein_coding

tolerated(0.2)

benign(0.15)

TCGA-AO-A128-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

doxorubicin

EIF5B

SNV

Missense_Mutation

c.2488N>A

p.Gly830Ser

p.G830S

O60841

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-BH-A0HF-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

arimidex

EIF5B

SNV

Missense_Mutation

c.1795N>T

p.Arg599Trp

p.R599W

O60841

protein_coding

deleterious(0)

possibly_damaging(0.869)

TCGA-BH-A0HU-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

docetaxel

EIF5B

SNV

Missense_Mutation

c.3313N>G

p.Arg1105Gly

p.R1105G

O60841

protein_coding

deleterious(0.01)

probably_damaging(0.998)

TCGA-D8-A1J8-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

nolvadex

EIF5B

SNV

Missense_Mutation

c.2654N>C

p.Gly885Ala

p.G885A

O60841

protein_coding

deleterious(0.01)

probably_damaging(0.974)

TCGA-E9-A243-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

5-fluorouracil

EIF5B

SNV

Missense_Mutation

c.1672N>A

p.Glu558Lys

p.E558K

O60841

protein_coding

tolerated(0.62)

benign(0.073)

TCGA-C5-A1MK-01

Cervix

cervical & endocervical cancer

Female

>=65

III/IV

Chemotherapy

carboplatin

EIF5B

SNV

Missense_Mutation

novel

c.916N>A

p.Glu306Lys

p.E306K

O60841

protein_coding

deleterious_low_confidence(0.01)

benign(0.012)

TCGA-C5-A905-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

EIF5B

SNV

Missense_Mutation

novel

c.1931N>G

p.Lys644Arg

p.K644R

O60841

protein_coding

deleterious(0.01)

probably_damaging(0.999)

TCGA-DS-A1OD-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1